Our Take
This is a maturity certification, not a technology breakthrough—and the real story is how a self-pay environment forced institutional discipline on data governance that most healthcare systems avoid.
Why it matters
Healthcare providers in resource-constrained markets (and that includes most of the world) often skip formal analytics governance in favor of ad-hoc reporting. Narayana's Stage 6 validation shows that institutional rigor and cost pressure can move together, not against each other.
Do this week
Clinical leaders: audit whether your analytics team reports to IT or to the business; if IT, request a structural review before your next major model deployment so accountability for outcomes is clear.
Narayana's analytics bet paid off with a maturity stamp
Narayana Institute of Cardiac Sciences, part of Narayana Health, became the first organisation in India to achieve Stage 6 validation under the HIMSS Analytics Maturity Assessment Model (AMAM), which measures healthcare organisations' capabilities and maturity in analytics.
The organisation serves 1.4 billion people across India's fragmented healthcare landscape, operating primarily in a self-pay model where patients bear direct cost risk. That constraint shaped everything: Narayana's analytics strategy was built from day one around operational precision. Senior clinicians were given visibility into metrics like length of stay, procedure material costs, blood transfusions, re-exploration after surgery, mortality, morbidity, and infection rates.
The move from fragmented spreadsheet reporting across 15 hospitals to a centralised enterprise intelligence platform supporting over 200 solutions (per company reporting) took deliberate structural choices. Narayana treated data intelligence and AI as a business function, not a technology function. The analytics team sits outside IT and reports to the CEO, with a dedicated centre of excellence embedded into operations. That structural choice meant analytics was not treated as a support service waiting to be asked for reports, but as part of how the organisation thinks and decides.
A second decision: Narayana rejected the idea that data quality had to be fully solved before analytics could begin. Instead, the organisation launched its data intelligence programme with the data it had, using early insights to expose gaps and process weaknesses. Data intelligence and data quality improved together.
One concrete output: Medha Scribe, an internally-built ambient AI scribe deployed for echocardiography, ultrasound, and radiology workflows. After deployment, average turnaround from study billing to report sign-off fell from 7.1 hours to 2.3 hours, a 68% reduction (company-reported), with 100% adoption and no additional reporting workforce. Operationally, analytics-driven visibility into outpatient delays helped reduce waiting times by 30%, while discharge turnaround dropped by 33% over time (company-reported).
Stage 6 forced Narayana to see what it had not yet formalised
The HIMSS AMAM framework required the organisation to assess what was demonstrably in place, not merely asserted. It required documentation of not just what had been built, but how consistently analytics was being used, how deeply it was embedded in clinical and operational workflows, and what governance structures ensured integrity.
The validation surfaced three central gaps. First: outcome attribution. Narayana measures outcomes and adoption, but lacks a standardised methodology linking specific analytics and AI initiatives to quantified improvements across clinical, operational, and financial domains. Second: AI transparency at portfolio scale. While model-level governance is clinician-led, the organisation lacks a single enterprise view of every model in production, including intended use, validation evidence, subgroup performance, and lifecycle status. Third: patient voice. Patient-reported outcomes have begun in pockets but are not yet feeding clinician workflows or enterprise outcome dashboards in a structured, decision-grade way.
According to Vivek Rajagopal, group chief analytics and AI officer at Narayana Health, these gaps point to a broader pattern: in some areas, execution had moved ahead of formalisation. The organisation was doing the right things but had not always systematised them.
Lock governance before you scale model count
The validation revealed that as Narayana deploys an increasing number of predictive models and AI-assisted tools across clinical and operational domains, the structures governing their development, validation, deployment, and ongoing monitoring become critical. Outcome attribution will require linking data across the care pathway to isolate the effect of specific interventions and control for confounding factors. Integrating patient-reported outcomes and experience data will give the organisation a fuller picture of care quality, including how patients experience care, functional recovery, and quality of life after treatment. This is not a post-deployment refinement; it is a governance architecture that needs to exist before models go into production at scale.